FibroGen, Inc. (NASDAQ:FGEN) Short Interest Update

FibroGen, Inc. (NASDAQ:FGEN) saw a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 5,300,000 shares, a growth of 79.7% from the February 13th total of 2,950,000 shares. Currently, 5.4% of the company’s stock are sold short. Based on an average trading volume of 3,330,000 shares, the short-interest ratio is presently 1.6 days.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of FibroGen in a report on Thursday, February 20th. StockNews.com assumed coverage on FibroGen in a research report on Friday. They issued a “hold” rating for the company.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FGEN. FMR LLC raised its holdings in shares of FibroGen by 21.8% in the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 68,569 shares during the period. Geode Capital Management LLC raised its stake in shares of FibroGen by 3.1% in the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after buying an additional 32,884 shares during the period. JPMorgan Chase & Co. raised its stake in shares of FibroGen by 430.7% in the third quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock valued at $668,000 after buying an additional 1,358,194 shares during the period. Franklin Street Advisors Inc. NC lifted its position in shares of FibroGen by 100.0% during the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 100,000 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of FibroGen by 80.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after acquiring an additional 605,572 shares during the period. 72.71% of the stock is currently owned by hedge funds and other institutional investors.

FibroGen Trading Up 2.9 %

Shares of FGEN stock traded up $0.01 during trading on Friday, hitting $0.44. The company’s stock had a trading volume of 1,204,677 shares, compared to its average volume of 2,324,187. The business has a fifty day moving average of $0.51 and a 200-day moving average of $0.43. FibroGen has a 52 week low of $0.18 and a 52 week high of $2.80. The company has a market cap of $44.27 million, a PE ratio of -0.36 and a beta of 0.82.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.